Frontier Medicines Corp.

Biopharmaceutical venture capital fundraising is on the rise in 2024, boosted in part by surging numbers of $100m-plus mega-rounds, including a pair of large financings that ended June and started Jul

Frontier Medicines Corp. has raised $235.5m in venture capital to date, including an $80m series C round unveiled on 22 February, although this latest financing is slightly smaller than its $88.5m se

The Alliance for Regenerative Medicine reported on 22 November that cell and gene therapy companies have raised enough money already in 2021 to break the record set in 2020. Venture capital financings

Amylyx Pharmaceuticals, Inc. announced Phase II/III results for AMX0035 in the treatment of amyotrophic lateral sclerosis (ALS) last year and hoped to obtain US Food and Drug Administration approval